1/2013 Moodi 39 VIITELUETTELO 1. Krogerus L, Kholová I. Sytologia syntyy uudelleen. Duodecim 130: 2387-2388, 2014. 2. Atula T, Tarkkanen J, Aro K. Kaulakyhmy – ohutneulabiopsia diagnostiikassa ja hoidon suunnittelussa. Duodecim 130: 2405-2412, 2014. 3. Boyd S, Arola J, Mäkisalo H, Färkkilä M. Sytologia ratkaisevassa roolissa primaa-risen sklerosoivan kolangiitin seulonnassa ja seurannassa. Duodecim 130: 2397- 2404, 2014. 4. Lappi-Blanco E, Mäkinen JM, Jartti A, Mali P, Kaarteenaho R. Keuhkosyöpien tar-kentuva diagnostiikka. Duodecim 128: 2225-2235, 2012. 5. Schmitt FC, Longatto-Filho A, Valent A, Vielh P. Molecular techniques in cyto-pathology practice. J Clin Pathol 61:258-267, 2008. 6. Schmitt FC. Cells carry the clue for targeted treatment: a new horizon for cyto-pathology. Cytopathology 18: 275-277, 2007. 7. Hughes AE, Magrini V, Demeter R, ym. Clonal architecture of secondary acute myeloid leukemia defined by single-cell sequencing. PLoS Genet 10: e1004462, 2014. 8. Knuuttila A, Salmenkivi K. Keuhkosyövän uudet hoidot edellyttävät tarkentu-nutta diagnostiikkaa. Duodecim 128: 2187-2189, 2012. 9. Travis WD, Brambilla E, Noguchi M, ym. International association for the study of lung cancer/American thoracic society/European respiratory society interna-tional multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6: 244-285, 2011. 10. Scagliotti GV, Parikh P, von Pawel J, ym. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive pa-tients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543- 3551, 2008. 11. Schiller JH, Harrington D, Belani CP, ym. Comparison of four chemotherapy regi-mens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002. 12. Salmenkivi K, Knuuttila A. Ei-pienisoluisen keuhkosyövän ALK-diagnostiikka. Duodecim 130: 701-704, 2014. 13. Schmitt FC. Thyroid cytology: FNA is still the best diagnostic approach. Cytopat-hology 17: 211-212, 2006. 14. Ali CZ, Cibas ES. The Bethesda system for reporting thyroid cytopathology: defi-nitions, criteria and explanatory notes. New York: Springer 2010, 1-166. 15. Arola J, Kholová I, Timonen T, Krogerus L. Bethesda-järjestelmä kilpirauhasen sytologiassa. Duodecim 126: 2449-2253, 2010. 16. Kholová I, Ludvíková M, Ryska A, Topolcan O, Pikner R, Pecen L, Cáp J, Holubec L Jr. Diagnostic role of markers dipeptidyl peptidase IV and thyroid peroxidase in thyroid tumors. Anticancer Res 23: 871-875, 2003. 17. de Matos LL, Del Giglio AB, Matsubayashi CO, de Lima Farah M, Del Giglio A, da Silva Pinhal MA. Expression of CK-19, galectin-3 and HBME-1 in the differentiati-on of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol 7: 97, 2012. 18. Paunovic I, Isic T, Havelka M, Tatic S, Cvejic D, Savin S. Combined immunohis-tochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors. APMIS 120: 368-379, 2012. 19. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 7: 569-580, 2011. 20. Xing M, Haugen BR, Schlumberger M: Progress in molecular-based manage-ment of differentiated thyroid cancer. Lancet 381: 1058-1069, 2013. 21. Hassell LA, Gillies EM, Dunn ST. Cytologic and molecular diagnosis of thyroid cancer. Is it time for routine reflex testing? Cancer Cytopathology 120: 7-17, 2012. 22. Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN: Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin En-docrinol Metab 94: 2092-2098, 2009. 23. Krogerus L, Andersson LC. A simple method for the preparation of paraffin-em-bedded cell blocks from fine needle aspirates, effusions and brushing. Acta Cy-tol 32: 585-587, 1988. 24. Crapanzano JP, Heymann JJ, Monaco S, Nassar A, Sagi A. The state of cell block variation and satisfaction in the era of molecular diagnostics and personalized medicine. Cytojournal 11: 7, 2014. 25. Jain D, Mathur SR, Iyer VK. Cell blocks in cytopathology: a review of preparati-ve methods, utility in diagnosis and role in ancillary studies. Cytopathology 25: 356-371, 2014. 26. Schmitt F, Cochand-Priollet B, Tötsch M, Davidson B, Bondi A, Vielh P. Immu-nocytochemistry in Europe: results of the European Federation of Cytology So-cieties (EFCS) inquiry. Cytopathology 22: 238-242, 2011. 27. Gissmann L, Wolnik L, Ikenberg H, Koldovsky U, Schnürch HG, zur Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci U S A 80: 560-563, 1983. 28. Dürst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A 80: 3812-3815, 1983. 29. Papanicolaou GN, Traut HF. The Diagnostic Value of Vaginal Smears in Carcin-oma of the Uterus. Am J Obst Gynec 42: 193, 1941 30. Traut HF, Papanicolaou GN. Cancer of the Uterus: The Vaginal Smear in Its Diag-nosis. Cal West Med 59: 121-122, 1943. 31. Toikkanen U. Papa-seulontojen kehittäjä täytti 100 vuotta. Suomen Lääkärileh-ti 70: 14-15, 2015. 32. Anttila A, Kotaniemi-Talonen L, Leinonen M, Hakama M, Laurila P, Tarkkanen J, Malila N, Nieminen P. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology tria-ge: randomised study within organised screening programme. BMJ 340: c1804, 2010. 33. Leinonen MK, Nieminen P, Lönnberg S, Malila N, Hakama M, Pokhrel A, Laurila P, Tarkkanen J, Anttila A. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA tes-ting: prospective randomised trial in Finland. BMJ 345: e7789, 2012. 34. Kares S, Kujala P, Vuento R, ym. HPV testing as the primary screening method in an organized regional screening program for cervical cancer. Preliminary re-sults. Cytopathology 25(suppl 1): 19, 2014. 35. Kholová I, Kares S, Veijalainen O, Vuento R, Tirkkonen M, Mäenpää J, Kujala P. Primary HPV screening in Tampere city: follow up data. Cytopathology 26: 19- 27, 2015. 36. Nieminen P, Timonen T. Gynekologisen irtosolunäytteen, papakokeen tulevai-suus. Duodecim 130: 2391-2395, 2014. 37. Anttila A, Pukkala E, Söderman B, Kallio M, Nieminen P, Hakama M. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963- 1995: recnt increase in cervical cancer incidence. Int J Cancer 65: 59-65, 1999. 38. Terveyden ja hyvinvoinnin laitoksen asettaman papilloomavirustautien torjun-taryhmän selvitys 30.4.2011. Terveyden ja hyvinvoinninlaitos. Raportti 28/2011. 39. Salo H, Nieminen P, Kilpi T, ym. Divergent coverage, frequency and costs of orga-nised and opportunistic Pap testing in Finland. Int j Cancer 135: 204-213, 2013. 40. Davis M, Feldman S. Making sense of cervical screening guidelines and recom-mendations. Curr Treat Options in Oncol 16:55, 2015. 41. Leino T, Salo H, Vänskä S. Miksi HPV-rokote tulee tänä syksunä rokotusohjel-maan? Suomen Lääkärilehti 68: 2538-2539, 2013. 42. Leinonen MK, Antilla A, Nieminen P. Papilloomavirustarunta ja HPV-testin toi-mivuus kohdunkaulan syövän seulonnassa. Suomen Lääkärilehti 70: 1243-1250, 2015. 43. Cummings MC, Marquart L, Pelecanos AM, Perkins G, Papadimos D, O’Rour-ke P, Ross JA. Which are more correctly diagnosed: conventional Papanicolaou smears or Thinprep samples? A comparative study of 9 years of external quali-ty- assurance testing. Cancer Cytopathol 123: 108-116, 2015. 44. Abedi-Ardekani B, Vielh P. Is liquid-based cytology the magic bullet for perfor-ming molecular techniques? Acta Cytol 58: 574-581, 2014. 45. Roszel JF. Cellular studies of peripheral blood and spinal fluid of mice with deve-loping tumors. Acta Cytol 9: 298-303, 1965. 46. Frost JK, Gill GW, Hankins AG, LaCorte FJ, Miller RA, Hollander DH. Cytology filter preparations: factors affecting their quality for study of circulating cancer cells in the blood. Acta Cytol 11: 363-373, 1967. 47. Gurian JM, West JT. Relationship of size of blood sample to yield of “positive” patients in studies of circulating tumor cells. J Natl Cancer Inst 31: 1431-1443, 1963. 48. Young R, Pailler E, Billiot F, Drusch F, Barthelemy A, Oulhen M, Besse B, Soria JC, Farace F, Vielh P. Circulating tumor cells in lung cancer. Acta Cytol 56: 655- 660, 2012. 49. D’Arcangelo M, Margetts J, Greystoke A. The use of circulating biomarkers in early clinical trials in patients with cancer. The use of circulating biomarkers in early clinical trials in patients with cancer. Biomark Med 9: 1011-1023, 2015. 50. Marotti JD, Rao KP, Brister KJ, ym. Cytologic rapid on-site evaluation of transtho-racic computed tomography – guided lung needle biopsies: who should perform ROSE? A cross-institutional analysis of procedural and diagnostic outcomes. J Am Soc Cytopathol 4: 160-169, 2015. 51. Olson MT, Ali SZ. Cytotechnologist on-site evaluation of pancreas fine needle aspiration adequacy: comparison with cytopathologists and correlation with the final interpretation. Acta Cytologica 56: 340-346, 2012. 52. Olson MT, Novak A, Kirby J, Shahid H, Boonyaarunnate T, Ali SZ. Cytotechnolo-gist- attended on-site evaluation of adequacy for metastatic disease involving bone and soft tissue. Acta Cytologica 57: 550-556, 2013. 53. Schmidt RL, Witt BL, Lopez-Calderon LE, Layfield LJ. The influence of rapid on-site evaluation on the adequacy rate of fine needle aspiration cytology. Am J Clin Pathol 139: 300-308, 2013. 54. Pambuccian SE. What is atypia? Use, misuse and overuse of the term atypia in diagnostic cytopathology. J Am Soc Cytopathol 4: 44-52, 2015. 55. Wojcik E. What should not be reported as atypia in urine cytology. J Am Soc Cy-topathol 4: 30-36, 2015. 56. Nayar R, Wilbur D (Ed). The Bethesda System for reporting cervical cytology: 3rd edition. New York: Springer 2015, 1-313. 57. Pitman MB, Layfield LJ. Guidelines for pancreaticobiliary cytology from the Pa-panicolaou Society of Cytopathology: A review. Cancer Cytopathol 122: 399-411, 2014. 58. Rosenthal DL, Wojcik EM, Kurtycz DFI (Ed). The Paris System for Reporting Urinary Cytology. New York: Springer 2015, 1-220. 6/2015 Moodi 207
Moodi No 6 / 2015
To see the actual publication please follow the link above